Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold.
作者信息
Arulananda Surein, Mitchell Paul
机构信息
Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.
School of Cancer Medicine, La Trobe University, Heidelberg, Australia.
出版信息
Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S388-S392. doi: 10.21037/tlcr.2018.08.12.
Abstract
摘要
相似文献
1
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold.
Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S388-S392. doi: 10.21037/tlcr.2018.08.12.
2
Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).
Clin Lung Cancer. 2013 Nov;14(6):674-9. doi: 10.1016/j.cllc.2013.05.001. Epub 2013 Jul 25.
3
Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
Lung Cancer. 2001 Dec;34 Suppl 3:S39-43. doi: 10.1016/s0169-5002(01)00381-6.
4
Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Cancer Prev Control. 1997 Dec;1(5):366-78.
5
[Medical treatment for stage III non-small-cell lung cancer (NSCLC)].
Gan To Kagaku Ryoho. 2007 Jun;34(6):841-8.
6
A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
J Med Invest. 2018;65(1.2):90-95. doi: 10.2152/jmi.65.90.
7
Behavioural biology: fortune favours bold and shy personalities.
Curr Biol. 2004 Jun 22;14(12):R470-2. doi: 10.1016/j.cub.2004.06.011.
8
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
Lung Cancer. 2016 Oct;100:30-37. doi: 10.1016/j.lungcan.2016.07.026. Epub 2016 Jul 27.
9
Human endurance and AI: Audentes Fortna Iuvat - fortune favours the bold.
Perfusion. 2019 Nov;34(8):627-628. doi: 10.1177/0267659119886462.
10
[Treatment of the unresectable non small cell lung carcinoma].
Cas Lek Cesk. 2005;144(9):602-12; discussion 612-3.
引用本文的文献
1
Single-Round LDCT Screening in Men Aged ≥ 70 Years: Prevalence of Pulmonary Nodules and Lung Cancer Detection.
Cancers (Basel). 2025 Jul 11;17(14):2318. doi: 10.3390/cancers17142318.
2
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2169531. doi: 10.1080/21645515.2023.2169531. Epub 2023 Jan 30.
3
Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
Transl Lung Cancer Res. 2020 Apr;9(2):188-203. doi: 10.21037/tlcr.2020.02.14.
本文引用的文献
1
The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Mar;13(3):426-435. doi: 10.1016/j.jtho.2017.11.135. Epub 2018 Jan 8.
2
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
3
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Ann Oncol. 2017 Apr 1;28(4):777-783. doi: 10.1093/annonc/mdx009.
4
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25.
5
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.
6
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Cancer Med. 2013 Dec;2(6):916-24. doi: 10.1002/cam4.142. Epub 2013 Oct 16.
7
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.
8
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.
J Thorac Oncol. 2013 Sep;8(9):1181-9. doi: 10.1097/JTO.0b013e3182988348.
9
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).
Lancet Oncol. 2012 Jul;13(7):671-8. doi: 10.1016/S1470-2045(12)70139-0. Epub 2012 May 22.
10
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology.
Ann Oncol. 2012 Jul;23(7):1730-8. doi: 10.1093/annonc/mdr565. Epub 2011 Dec 9.
Zotero 插件